Construction of chimeric IL-21 recombinant oncolytic influenza virus and mechanisms for its antitumor efficacy against hepatocellular carcinoma

Authors: CAO Rui, ZENG Guineng, TIAN Yuying

Source: 陆军军医大学学报, Vol 46, Iss 24, Pp 2736-2744 (2024)

Subject Terms: oncolytic virus, reverse genetic technology, combination therapy, il-21, anti-programmed cell death protein 1 antibody, hepatocellular carcinoma, Medicine (General), R5-920

File Description: electronic resource

Relation: https://aammt.tmmu.edu.cn/html/202407051.htm; https://doaj.org/toc/2097-0927

Access URL: https://doaj.org/article/0fbabbbaae6e45d99cf2cd5817ba69b1

Resveratrol alleviates testicular toxicity induced by anti-PD-1 through regulating the NRF2-SLC7A11-GPX4 pathway

Authors: Halahati· Tuerxun, Yixin Zhao, Yawen Li, Xingyu Liu, Shuhui Wen, Yuguang Zhao

Source: Frontiers in Immunology, Vol 16 (2025)

Subject Terms: immune checkpoint inhibitors, anti-programmed cell death protein 1, reproductive toxicity, oxidative stress, ferroptosis, resveratrol, Immunologic diseases. Allergy, RC581-607

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fimmu.2025.1529991/full; https://doaj.org/toc/1664-3224

Access URL: https://doaj.org/article/0e8328f999124bfab289c0a853c5c9f5

Challenges in autoimmune polyendocrine syndrome type 2 with the full triad induced by anti-programmed cell death 1: a case report and review of the literature

Authors: Qin Pan, Ping Li

Source: Frontiers in Immunology, Vol 15 (2024)

Subject Terms: anti-programmed cell death protein 1, autoimmune polyendocrine syndrome type 2, adrenal insufficiency, adrenal crisis, hypothyroidism, type 1 diabetes mellitus, Immunologic diseases. Allergy, RC581-607

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fimmu.2024.1366335/full; https://doaj.org/toc/1664-3224

Access URL: https://doaj.org/article/e7050035e11944b99eed05855890c41e

Chemo-free maintenance therapy in adult T-cell acute lymphoblastic leukemia: A case report and literature review

Authors: Yuanbin Song, Shuzhao Chen, Chenfei Liu, Lezong Chen, Weida Wang, Bingyi Wu, Yang Liang

Source: Frontiers in Pharmacology, Vol 14 (2023)

Subject Terms: chemo-free maintenance therapy, anti-programmed cell death protein 1, histone deacetylase inhibitor, T-cell acute lymphoblastic leukemia, case report, literature review, Therapeutics. Pharmacology, RM1-950

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fphar.2023.1051305/full; https://doaj.org/toc/1663-9812

Access URL: https://doaj.org/article/5c0ab6bca1034f6b972e539ab5808868

Higher Enhancement Intrahepatic Nodules on the Hepatobiliary Phase of Gd-EOB-DTPA-Enhanced MRI as a Poor Responsive Marker of Anti-PD-1/PD-L1 Monotherapy for Unresectable Hepatocellular Carcinoma

Authors: Tomoko Aoki, Naoshi Nishida, Kazuomi Ueshima, Masahiro Morita, Hirokazu Chishina, Masahiro Takita, Satoru Hagiwara, Hiroshi Ida, Yasunori Minami, Akira Yamada, Keitaro Sofue, Masakatsu Tsurusaki, Masatoshi Kudo

Source: Liver Cancer, Pp 1-14 (2021)

Subject Terms: anti-programmed cell death protein 1, programmed death-ligand 1 antibody, hepatocellular carcinoma, gadolinium-ethoxybenzyl-diethylenetriamine-enhanced magnetic resonance imaging, wnt/β-catenin, imaging biomarker, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.karger.com/Article/FullText/518048; https://doaj.org/toc/2235-1795; https://doaj.org/toc/1664-5553

Access URL: https://doaj.org/article/c9b5b243f219433ab8ac74e5a5b8bccc

Pembrolizumab Treatment-Induced Liver Toxicity

Authors: Benoît Calderon, Alma Stancu, François-Roger Vanel, Léa Vazquez

Source: Case Reports in Gastroenterology, Vol 15, Iss 2, Pp 742-750 (2021)

Subject Terms: anti-programmed cell death protein 1, pembrolizumab, immune-mediated hepatitis, lung adenocarcinoma, Diseases of the digestive system. Gastroenterology, RC799-869

File Description: electronic resource

Relation: https://www.karger.com/Article/FullText/518128; https://doaj.org/toc/1662-0631

Access URL: https://doaj.org/article/6824839258874d3cbf6831f21c643224

Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors

Authors: Satya Das, Douglas B. Johnson

Source: Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-11 (2019)

Subject Terms: Immune-related adverse events, Immune checkpoint inhibitor efficacy, Autoimmunity and anti-tumor effect, Anti-programmed cell death protein 1, Anti-programmed death-ligand 1, Anti-cytotoxic T-lymphocyte-associated protein 4, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: http://link.springer.com/article/10.1186/s40425-019-0805-8; https://doaj.org/toc/2051-1426

Access URL: https://doaj.org/article/06976945baba47cdb4438ab4066e4554

Late-onset isolated adrenocorticotropic hormone deficiency caused by nivolumab: a case report

Authors: Ayumu Takeno, Masahiro Yamamoto, Miwa Morita, Sayuri Tanaka, Ippei Kanazawa, Mika Yamauchi, Sakae Kaneko, Toshitsugu Sugimoto

Source: BMC Endocrine Disorders, Vol 19, Iss 1, Pp 1-5 (2019)

Subject Terms: Anti-programmed cell death protein 1 antibody, Anti-cytotoxic T-lymphocyte-associated protein 4 antibody, Nivolumab, Isolated adrenal deficiency, Thyroid dysfunctions, Diseases of the endocrine glands. Clinical endocrinology, RC648-665

File Description: electronic resource

Relation: http://link.springer.com/article/10.1186/s12902-019-0335-x; https://doaj.org/toc/1472-6823

Access URL: https://doaj.org/article/f5b64b416df54b658f47a131562f1d32

Successful Treatment of Refractory Squamous Cell Cancer of the Head and Neck with Nivolumab and Ipilimumab

Authors: Katjana S. Schwab, Glenn Kristiansen, Hans H. Schild, Stefanie E.A. Held, Annkristin Heine, Peter Brossart

Source: Case Reports in Oncology, Vol 11, Iss 1, Pp 17-20 (2018)

Subject Terms: Nivolumab, Ipilimumab, Squamous cell carcinoma, Anti-PD-1 inhibitor, Anti-CTLA4 antibody, Anti-programmed cell death protein 1 inhibitor, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.karger.com/Article/FullText/485562; https://doaj.org/toc/1662-6575

Access URL: https://doaj.org/article/af56c7c0dae948ba8dee48309c4f1132

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.